Clinical Trials Logo
  1. Home
  2. Bone and Joint Infection
  3. NCT04662736
  4. Details
NCT04662736 Clinical Trial

Tedizolid Suppressive Antimicrobial Therapy in a Reference Center

Bone and Joint Infection Clinical Trial

— TediSAT  

Official title:
Tedizolid Suppressive Antimicrobial Therapy

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04662736
Other study ID # 232
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 1, 2021
Est. completion date April 1, 2021

Study information
Verified date June 2021
Source Hospices Civils de Lyon
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

the aim of the study is to describe the management and outcome of patients having an osteo-articular infection treated by tedizolid as a suppressive antibiotic therapy.

Recruitment information / eligibility
Status Completed
Enrollment 17
Est. completion date April 1, 2021
Est. primary completion date February 1, 2021
Accepts healthy volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - patients having an osteo-articular infection treated with tedizolid as a suppressive antibiotic therapy Exclusion Criteria: -

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic therapy
description of osteo-articular infection managed with tedizolid as a suppressive antibiotic therapy

Locations
Country Name City State
France Hospices Civils de Lyon Lyon

Sponsors (1)
Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary rate of patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic therapy proportion of patients having tedizolid as a suppressive antibiotic therapy between 2016 and 2021
Primary rate of failure in patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic proportion of patients having a failure under tedizolid as a suppressive antibiotic therapy 2 years
Primary rate of adverse event in patients having had a BJI/PJI treated with tedizolid as a suppressive proportion of patients having a adverse event under tedizolid as a suppressive antibiotic therapy through study completion, an average of 1 year
Primary Description of patients having had a BJI/PJI treated with tedizolid as a suppressive type of patients: age, CMI, comorbidities... 2 years
Primary Description of BJI/PJI treated with tedizolid as a suppressive implant or prothese or not, acute/ chronic, bacteriology 2 years
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05421312 - Periarticular Penetration of Cefazolin and Clindamycin in Second Stage Revision Arthroplasty of the Hip Phase 4
Active, not recruiting NCT04563325 - Oral-only Antibiotics for Bone and Joint Infections in Children Phase 4
Completed NCT03627000 - Microbiological Epidemiology in Patients Experiencing Microbiological or Clinical Failure Following Reimplantation After a 2-stage Exchange Strategy for Hip or Knee Prosthetic Joint Infection
Completed NCT03311113 - Adherence to Oral Antibiotics In Patients With Osteoarticular Infections
Recruiting NCT05753215 - Controlled Trial of Omadacycline Randomized Treatment Given for Bone and Joint Infection Phase 2
Completed NCT03209921 - Pharmacokinetic Variability of Daptomycin During Prolonged Therapy for Bone and Joint Infections N/A
Completed NCT04418882 - Septic Management and Outcome of Open Fracture
Completed NCT05248490 - Impact of Pharmaceutical Interviews Regarding the Management of Adverse Effects Related to the Antibiotic Therapy Used to Treat Osteoarticular Infections During Return Home N/A
Completed NCT03624855 - Implant-Associated P. Aeruginosa Bone And Joint Infections : Experience In A Regional Reference Center In France
Recruiting NCT04496024 - Ofloxacin Concentration-toxicity Relationship in the Elderly N/A
Recruiting NCT04933344 - Pharmacokinetics and Toxicodynamics of Daptomycin in Bone and Joint Infections
Recruiting NCT04538053 - BonE and Joint Infections - Simplifying Treatment in Children Trial Phase 4
Completed NCT04373278 - Infection After Free Fibula Flap Reconstruction of the Mandible: a Retrospective Cohort Study
Completed NCT03209934 - Daptomycin > 6 mg/kg/Day as Salvage Therapy in Patients With Complex Bone and Joint Infection: Cohort Study in a Regionalreference Center N/A
Recruiting NCT02817711 - Lyon BJI Cohort Study N/A
Recruiting NCT03611634 - Consitution Of A Biological Collection From Samples From The Gut Microbiote In Patients Having A Bone Or Joint Infection Treated By A Suppressive Subcutaneous Antibiotherapy With Betalactamine
Completed NCT03177369 - Teicoplanin-based Antimicrobial Therapy in Staphylococcus Aureus Bone and Joint Infection: Tolerance, Efficacy and Experience With Subcutaneous Administration N/A
Recruiting NCT04722926 - Lyon PJI Retrospective Cohort Study
Completed NCT03852784 - Osteoarticular Infections With Pneumococcal
Recruiting NCT03796104 - Prognostic Impact of Delta-haemolysin Production Deficiency in Staphylococcus Aureus on the Prognosis of Infected Implant Treated by DAIR

External Links